Kronos Bio, Inc. (KRON) Research

Kronos Bio, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the identification and advancement of innovative therapies for cancer. Its therapeutic strategy centers on modulating dysregulated transcription factors and the intricate transcriptional regulatory networks that fuel oncogenic activity. The company's primary investigational drug, entospletinib (ENTO), is an orally administered, selective inhibitor of spleen tyrosine kinase (SYK), designed for patients with acute myeloid leukemia. A registrational Phase 3 clinical trial is slated to evaluate ENTO in combination with induction chemotherapy for acute myeloid leukemia patients who possess NPM1 mutations. Furthermore, Kronos Bio is progressing KB-0742, an orally bioavailable cyclin dependent kinase 9 (CDK9) inhibitor, which is currently undergoing Phase 1/2 clinical assessment for the treatment of MYC-amplified solid tumors. Established in 2017, the company maintains its headquarters in San Mateo, California.

Market snapshot

Symbol
KRON
Price
$0.88
Day change
+1.49%
Market cap
$53.7M
P/E ratio
-1.57x
52-week range
0.65-1.46
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$1.63

Peer companies

  • Achilles Therapeutics plc (ACHL)
  • AlloVir, Inc. (ALVR)
  • Aerpio Pharmaceuticals, Inc. (ARPO)
  • bluebird bio, Inc. (BLUE)
  • Lunai Bioworks Inc. (RENB)
  • Rein Therapeutics Inc. (RNTX)
  • Reneo Pharmaceuticals, Inc. (RPHM)
  • Sigilon Therapeutics, Inc. (SGTX)

Recent insider activity

  • Belldegrun Arie — D-Return (34000 shares) on 2025-06-20
  • Belldegrun Arie — D-Return (20600 shares) on 2025-06-20
  • Belldegrun Arie — U-Tender (679575 shares) on 2025-06-20
  • Belldegrun Arie — D-Return (34000 shares) on 2025-06-20
  • Belldegrun Arie — D-Return (34000 shares) on 2025-06-20

Open Kronos Bio, Inc. (KRON) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.